Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890735 | 0.80 | FOLH1 (0.40) | FOLH1ALDH1A1LMNAADRB2 | |
| SCHEMBL3729369 | 0.77 | FOLH1 (0.33) | FOLH1ALDH1A1LMNA | |
| SCHEMBL891085 | 0.76 | FOLH1 (0.42) | FOLH1ALDH1A1LMNAADRB2 | |
| SCHEMBL3725551 | 0.76 | FOLH1 (0.33) | FOLH1 | |
| SCHEMBL1900362 | 0.70 | FOLH1 (0.48) | FOLH1ALDH1A1LMNAADRB2 | |
| SCHEMBL25513626 | 0.69 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1996152 | 0.68 | ALDH1A1 (0.49) | ALDH1A1LMNA | |
| SCHEMBL25513622 | 0.68 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL6536333 | 0.68 | HSD11B1 (0.37) | — | |
| SCHEMBL25513619 | 0.68 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710091-B2 | Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug | IPSEN PHARMA S.A.S. (FR) | 2014-04-29 | — | — | US | disclosed |
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | MKI67, CCND2, CCND1 | FOLH1 4446/4885ALDH1A1 759/4885LMNA 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.